EP0155941A1 - Composition de mineraux injectables a usage veterinaire - Google Patents
Composition de mineraux injectables a usage veterinaireInfo
- Publication number
- EP0155941A1 EP0155941A1 EP84901728A EP84901728A EP0155941A1 EP 0155941 A1 EP0155941 A1 EP 0155941A1 EP 84901728 A EP84901728 A EP 84901728A EP 84901728 A EP84901728 A EP 84901728A EP 0155941 A1 EP0155941 A1 EP 0155941A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition according
- vitamin composition
- vitamin
- composition
- ruminants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims description 7
- 239000011707 mineral Substances 0.000 title claims description 7
- 229930003231 vitamin Natural products 0.000 claims abstract description 19
- 235000013343 vitamin Nutrition 0.000 claims abstract description 19
- 239000011782 vitamin Substances 0.000 claims abstract description 19
- 229940088594 vitamin Drugs 0.000 claims abstract description 19
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052751 metal Inorganic materials 0.000 claims abstract description 9
- 239000002184 metal Substances 0.000 claims abstract description 9
- 150000002739 metals Chemical class 0.000 claims abstract description 9
- 241000282849 Ruminantia Species 0.000 claims abstract description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052802 copper Inorganic materials 0.000 claims abstract description 6
- 239000010949 copper Substances 0.000 claims abstract description 6
- 229910052742 iron Inorganic materials 0.000 claims abstract description 6
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 6
- 239000011701 zinc Substances 0.000 claims abstract description 6
- 239000000470 constituent Substances 0.000 claims abstract description 5
- 239000011573 trace mineral Substances 0.000 claims abstract description 4
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 4
- 230000035558 fertility Effects 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 208000032484 Accidental exposure to product Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000000655 Distemper Diseases 0.000 claims description 2
- 241000282313 Hyaenidae Species 0.000 claims description 2
- 206010023126 Jaundice Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000004720 fertilization Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the present invention relates to a vitamin composition for veterinary use containing minerals and trace elements for correcting or improving the diet of ruminants.
- the invention also extends to the veterinary application of such injectable mineral compositions.
- vitamin E and selenium are both in liquid form. In addition, they are miscible with each other in large proportions so that there was no difficulty in presenting a mixture of said constituents in the form of an injectable composition.
- the applications of this known composition are numerous and include the treatment of muscular atrophies, digestive, cardiovascular, respiratory, nervous disorders.
- the British patent does not recommend any solution for parenterally administering minerals other than selenium.
- it is sometimes essential to administer metals such as iron, zinc and / or copper.
- the particular conformation of the digestive system causes a degradation of the vitamin composition, particularly due to the presence of ammonia in the rumen.
- This vitamin composition then largely loses its healing properties and irregular and non-reproducible results are observed.
- the present invention aims to remedy the drawbacks of administration by the digestive route and provides a vitamin composition for veterinary use containing minerals and trace elements with a view to correcting or improving the diet of ruminants.
- This composition is essentially characterized in that it also contains metals such as iron, zinc and / or copper dissolved in a physiologically acceptable solvent, in an injectable form.
- this composition optionally contains antibiotics.
- the above solvent is propylene glycol.
- Therapeutic applications are diarrhea in young animals, jaundice, distemper, rickets, anemia, diseases of the white muscles which cause deformations, disturbances in the liver, especially in the event of food overload or during accidental ingestion of harmful substances, abnormal development of the skeleton, muscles or skin, impaired growth, disturbance of fertilization at all stages and Hyena disease.
- the aforementioned vitamin composition advantageously has a preventive effect to avoid said diseases and to promote fertility in ruminants.
- the invention consists in having used for the dissolution of metals, a solvent which has in fact been used until now, only for the dissolution of antibiotics. It also consists in having discovered that this same solvent could dissolve antibiotics such as streptomycin dihydrosuifate and mix with traditional vitamin complexes consisting of axerophthol, nicotinic acid and cholecalciferol.
- antibiotics such as streptomycin dihydrosuifate and mix with traditional vitamin complexes consisting of axerophthol, nicotinic acid and cholecalciferol.
- the present invention aims to provide a remedy for these diseases or dysfunctions by a simple preparation which can be injected and which has a sufficiently broad spectrum to compensate for any deficiency or imbalance.
- composition of a pharmaceutical form of the vitamin complex according to the invention contains the following constituents (per 100 ml), as collated in Table I.
- Such a preparation can be injected at a rate of 1 to 40 ml / 100 kg of body weight, the injection being repeated every 5 to 8 days for example, but of course being modified according to veterinary requirements and / or prescriptions.
- the invention is therefore not limited to the strict embodiment as shown. Many variations and modifications can be made without removing it from the scope of the invention, determined by the fact that there are dissolved in a physiologically acceptable solvent, both vitamin complexes, metals such as iron, zinc and / or copper, and optionally antibiotics in a parenteral injectable form.
- the above drug composition can also be administered to humans, either orally or by parenteral injection at a rate of 0.1 to 4.0 ml / 10 kg of body weight, the injection being repeated every 3 to 8 Days for example, or as prescribed by the attending physician.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU84787 | 1983-05-03 | ||
| LU84787 | 1983-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0155941A1 true EP0155941A1 (fr) | 1985-10-02 |
Family
ID=19730091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP84901728A Pending EP0155941A1 (fr) | 1983-05-03 | 1984-05-02 | Composition de mineraux injectables a usage veterinaire |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0155941A1 (da) |
| JP (1) | JPH01500745A (da) |
| CA (1) | CA1226522A (da) |
| DK (1) | DK3685A (da) |
| IE (1) | IE58361B1 (da) |
| IT (1) | IT1180165B (da) |
| PT (1) | PT78541B (da) |
| WO (1) | WO1984004243A2 (da) |
| ZA (1) | ZA843279B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600586A (en) * | 1983-08-08 | 1986-07-15 | Green Milton L | Livestock feed lot adaptation composition and method |
| FR2599967B1 (fr) * | 1986-06-16 | 1989-03-31 | Bfb Etudes Rech Experimentale | Utilisation de sel de zinc et de la vitamine b6 pour enrayer les processus alopeciques et/ou seborrheiques. |
| NZ222664A (en) * | 1986-11-29 | 1990-06-26 | Vesta Med Pty Ltd | Pharmaceutical compositions containing pyridoxal as a source of vitamin b6 |
| FR2625414B1 (fr) * | 1987-12-31 | 1990-06-01 | Unicor Union Cooperatives Agri | Melange d'ingredients nutritionnels pour l'alimentation des ruminants |
| NZ272317A (en) * | 1995-06-09 | 1997-07-27 | Bomac Lab Ltd | Veterinary formulation; comprises calcium borogluconate, vitamin b12 or a derivative thereof and a carrier; treatment of milk fever in animals |
| WO1998006410A1 (en) * | 1996-08-12 | 1998-02-19 | Taisho Pharmaceutical Co., Ltd. | Zinc-containing composition |
| DE19731432C2 (de) * | 1997-07-22 | 1999-07-15 | Phoenix Lab Pharmazeutische Pr | Verwendung von Cholincitrat |
| BR112022000558A2 (pt) * | 2019-07-12 | 2022-03-15 | Chemvet Australia Pty Ltd | Suplemento nutricional injetável |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5176436A (ja) * | 1974-12-24 | 1976-07-02 | Kumiai Chemical Industry Co | Dobutsuyohinketsuyobo chiryozai |
| JPS6039681B2 (ja) * | 1976-01-01 | 1985-09-07 | 日本臓器製薬株式会社 | デキストリン・クエン酸・第二鉄多核複合体及び該複合体を含有する非経口用鉄剤 |
| EP0046409A1 (en) * | 1980-08-20 | 1982-02-24 | Erwin Günther Walliczek | A process for the preparation of a solution of a cuprous complex; solutions of the cuprous complexes for use in the therapeutic treatment of the human or animal body; and a method of therapeutic treatment of a plant |
| IL61080A0 (en) * | 1980-09-19 | 1980-11-30 | Garfinkel D | Pharmaceutical composition containing zinc ions |
-
1984
- 1984-05-02 JP JP59501884A patent/JPH01500745A/ja active Pending
- 1984-05-02 EP EP84901728A patent/EP0155941A1/fr active Pending
- 1984-05-02 IE IE108784A patent/IE58361B1/en not_active IP Right Cessation
- 1984-05-02 IT IT20758/84A patent/IT1180165B/it active
- 1984-05-02 ZA ZA843279A patent/ZA843279B/xx unknown
- 1984-05-02 WO PCT/BE1984/000011 patent/WO1984004243A2/fr not_active Ceased
- 1984-05-02 CA CA000453414A patent/CA1226522A/fr not_active Expired
- 1984-05-03 PT PT78541A patent/PT78541B/pt not_active IP Right Cessation
-
1985
- 1985-01-03 DK DK3685A patent/DK3685A/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3685D0 (da) | 1985-01-03 |
| DK3685A (da) | 1985-01-03 |
| PT78541A (fr) | 1984-06-01 |
| ZA843279B (en) | 1985-03-27 |
| WO1984004243A3 (fr) | 1985-03-14 |
| JPH01500745A (ja) | 1989-03-16 |
| CA1226522A (fr) | 1987-09-08 |
| PT78541B (fr) | 1986-07-14 |
| WO1984004243A2 (fr) | 1984-11-08 |
| IE58361B1 (en) | 1993-09-08 |
| IT1180165B (it) | 1987-09-23 |
| IT8420758A1 (it) | 1985-11-02 |
| IE841087L (en) | 1984-11-03 |
| IT8420758A0 (it) | 1984-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2124961B1 (fr) | Nouvelle composition à base d'oxime de cholest-4-èn-3-one | |
| Mathe et al. | Effects of the thyroid state on cholesterol metabolism in the rat | |
| US20240325471A1 (en) | Compositions containing curcumin having improved bioavailability | |
| CN105380962A (zh) | 一种降尿酸组合物及其制剂 | |
| EP0155941A1 (fr) | Composition de mineraux injectables a usage veterinaire | |
| FR2505184A1 (fr) | Procede de prevention de la paralysie vitulaire chez la vache laitiere | |
| US5679344A (en) | Glucosamine composition and method | |
| EP2868317A1 (en) | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol soft capsule and method for preparing same | |
| EP0280593B1 (fr) | Composition à base d'acide aminé et de vitamines utilisable en thérapeutique cancérologique | |
| Lansford Jr et al. | Effects of asparagine and other related nutritional supplements upon alcohol-induced rat liver triglyceride elevation | |
| NZ504177A (en) | Use of an extract of pepino (Solanum muricatum) and optionally liquorice for lowering blood alcohol concentration | |
| WO2007014379A2 (en) | A lipidic extract from lepidium meynii and its effect on the libido | |
| JPH07112979B2 (ja) | 活性酸素フリーラジカル消去剤 | |
| JP2009263295A (ja) | 性ホルモン誘発剤及びそれを用いたタンパク代謝改善、体質改善方法 | |
| JP2891738B2 (ja) | アルコール吸収抑制剤 | |
| JPH06199693A (ja) | 虚血性疾患改善治療剤 | |
| US6139863A (en) | Suppositories | |
| JP2003277284A (ja) | 抗酸化力増強剤 | |
| US20130029996A1 (en) | Special composition for the use thereof as a drug | |
| JPH08208464A (ja) | 高脂血症の治療及び予防薬 | |
| CA1221635A (fr) | Composition a activite pharmaceutique amelioree et utilisation de celle-ci pour des usages veterinaires | |
| US4434177A (en) | α-Methyldopa-L-ascorbic acid compositions | |
| US4321264A (en) | α-methyldopa compositions | |
| KR19990009411A (ko) | 간장질환치료에 우수한 의약조성물 | |
| KR0142809B1 (ko) | 간질환 치료용 약제조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19841231 |
|
| AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19870520 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SPEECKE, ANDRE |